Observational post-marketing registry exploring the safety and efficacy of the COMBO stent in an all-comer percutaneous coronary intervention (PCI) cohort

Trial Profile

Observational post-marketing registry exploring the safety and efficacy of the COMBO stent in an all-comer percutaneous coronary intervention (PCI) cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Acronyms MASCOT
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 23 Oct 2017 According to an OrbusNeich media release, data will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top